AstraZeneca Is Down 14%. What History Says About AZN

AstraZeneca Is Down 14% in 140 Days. What History Says

AstraZeneca PLC (AZN) is down 14% from its all-time high as of July 9, 2026, and has been falling for approximately 140 days. The Drawdown Severity Score™ stands at 3.0, placing the stock in the yellow zone. In 23 comparable prior drops of 10% or more, AstraZeneca took an average of 397 days to recover.

The Catalyst Driving AstraZeneca's Slide

On July 9, 2026, shares of AstraZeneca PLC experienced a sharp decline following disappointing clinical data. According to Blockonomi, the company's Wainua heart trial missed its primary endpoint, surprising many market participants. The drug, which was developed in partnership with Ionis Pharmaceuticals, failed to meet key efficacy metrics in its cardiovascular study.

This clinical setback had an immediate impact on the stock price. According to TradingKey, AstraZeneca stock moved down by 6.72% on July 9, 2026, marking one of its worst single-day performances of the year. This sudden drop broke a period of relative stability and accelerated a decline that had been quietly building for several months.

According to Seeking Alpha, while some analysts urged investors not to panic, the trial failure represents a notable hurdle for AstraZeneca's cardiovascular pipeline. The disappointment surrounding Wainua has forced the market to recalibrate its near-term growth expectations for the company. This shift in sentiment is the primary driver behind the stock's transition from the green zone to the yellow zone.

Deconstructing the Current Drawdown Numbers

As of July 9, 2026, AstraZeneca stock closed at $178.49. This price puts the stock exactly 14.4% below its all-time high of $208.62. The absolute decline of $30.13 per share has unfolded over a span of 139 days.

Our proprietary Drawdown Severity Score™ registers at 3.0 as of our July 9, 2026 data, which classifies the asset's risk profile as Moderately Elevated. This severity score indicates that the stock is experiencing a deeper and more prolonged correction than its typical historical pullbacks. The move into the yellow zone signals that the risk of further volatility has increased relative to the stock's historical baseline.

A look at the valuation snapshot from 2026-07-08 provides historical context for this price movement. The Price-to-Sales (P/S) ratio for AstraZeneca stands at 5.0, placing it in the 85th percentile of its own daily P/S record since 2006-07-07, which is above its historical median of 3.5. Meanwhile, its EV-to-EBITDA ratio is 16.3, sitting in the 63rd percentile of its daily record since 2006-07-07, slightly above its historical median of 14.2.

Historical Context: How Prior Drops Played Out

To understand the significance of a 14.4% drawdown, we must look at AstraZeneca's historical trading patterns. Our database has tracked a total of 200 historical drawdown events for this stock. Across all 200 of these events, the average maximum drawdown was just -4.6%, with an average drawdown duration of 58 days.

The current 139-day decline is already more than double the average historical duration. This indicates that the current sell-off is not a standard, short-term pullback. Instead, it represents a more structural correction that aligns with the stock's deeper historical cycles.

To find truly comparable periods, we look specifically at times when AstraZeneca dropped by 10% or more from its peak. Our data shows that the stock has experienced a drop of this magnitude exactly 23 times in its history. In those 23 comparable instances, the average duration of the drawdown was 397 days.

This historical baseline suggests that double-digit corrections for AstraZeneca are rarely resolved quickly. Once the stock enters this territory, it typically undergoes a prolonged period of consolidation before reclaiming its previous highs. The table below compares the current drawdown metrics against these historical benchmarks.

Industry Context and Competitive Pressures

The pharmaceutical industry is highly sensitive to clinical trial outcomes, where years of research can culminate in binary success or failure. AstraZeneca's recent trial miss with Wainua illustrates this industry-wide risk. According to Stock Titan, the missed primary endpoint has raised questions about the commercial viability of the treatment in a highly competitive cardiovascular market.

This setback occurs at a time when major pharmaceutical firms are competing fiercely for market share in key therapeutic areas. According to TradingView, investors frequently compare the long-term potential of AstraZeneca against other industry giants like Pfizer. While Pfizer has dealt with its own post-pandemic product transitions, AstraZeneca's pipeline setbacks create a different set of challenges for its valuation.

Additionally, AstraZeneca is navigating corporate structural changes. The company recently announced plans to complete a direct listing of its ordinary shares and all US debt securities on the New York Stock Exchange. While this direct listing simplifies its corporate structure, it does not shield the stock from the fundamental pressures of clinical trial results.

Analyzing the Drawdown Duration and Risk Profile

The 139-day duration of the current drawdown is a key metric for risk management. Because the average historical drawdown for AstraZeneca lasts only 58 days, the current span of nearly five months indicates a prolonged lack of buying pressure. The stock has struggled to find a firm bottom since starting its descent from $208.62.

The transition of the severity score to 3.0 highlights this shifting risk profile. In the green zone, pullbacks are typically brief and represent minor market noise. In the yellow zone, the drawdown has reached a depth and duration that historically requires significant time to resolve.

If history is any guide, the 23 previous drops of 10% or more show that patience is often required. With an average duration of 397 days for those deep drawdowns, the current 139-day period may only represent the middle phase of a larger cycle. Investors tracking the stock must consider whether the clinical pipeline can deliver positive news quickly enough to shorten this historical recovery timeline.

What Changes This: Factors to Monitor

For AstraZeneca to reverse its current trend, several operational and clinical milestones must be met. The most immediate catalyst would be positive data from other late-stage pipeline candidates. Success in its core oncology or respiratory portfolios could offset the disappointment of the Wainua cardiovascular trial.

We must also monitor the progress of the company's direct listing on the New York Stock Exchange. While listings themselves do not drive earnings, increased liquidity and visibility among US institutional investors can sometimes support trading volumes. Any changes in institutional ownership during this transition will be critical to watch.

Ultimately, the Drawdown Severity Score™ will serve as our primary guide for tracking AstraZeneca's recovery. A sustained move back toward the all-time high of $208.62 would reduce the drawdown depth and eventually lower the severity score. Conversely, if the stock breaks below its July 9, 2026, close of $178.49, the drawdown will deepen, potentially pushing the score higher into the yellow zone or toward the red zone.